On October 13, Cue Health announced a $481 million award from the Department of Defense (DoD), on behalf of the US Department of Health and Human Services (HHS), to expand Cue's US-based production capacity and deploy six million molecular, point-of-care Cue COVID-19 Tests through early 2021.
The deployment of substantial quantities of Cue's point-of-care COVID-19 Test will increase the national COVID-19 testing capacity and will significantly reduce the time to obtain molecular test results for individual patients to about 20 minutes. The effort is led by the DoD's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, in coordination with the DOD Joint Acquisition Task Force, and is funded through the HHS Office of the Assistant Secretary for Health to enable and support domestic production of critical medical resources.
The WilmerHale team advising Cue Health is led by Barry Hurewitz and Todd Rumberger.